Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06024694

Primary Mediastinal Large B-cell Lymphoma With CNS Involvement

Primary Mediastinal Large B-cell Lymphoma (PMBCL) Clinical Trial

Official title:
Retrospective Multicenter International Study on Prognostic Factors, Management And Outcome Of Primary Mediastinal Large B-Cell Lymphoma (PMLBCL) Patients With Central Nervous System (CNS) Involvement

Clinical Trial Summary

retrospective study focused on patients with a known diagnosis of PMLBCL which experienced a CNS relapse during the course of their disease to obtain information about the clinical characteristics, the management at diagnosis and at each relapses , and the outcome of these cases. The aim of the study is to put together the large International series on CNS+ PMLBCL data, coming from 6 different countries , on clinical factors, anti-lymphoma therapy administered alone or concomitant with CNS prophylaxis , the information about the site of re biopsy when available , the dose intensity of lymphoma therapy received at relapse and the outcome of patients. Both patients treated in routine practice or within clinical trials will be considered. Moreover to better characterized the pathological features of this rare entity a central pathological review of the initial diagnosis and when available of for histological confirmed relapse will be considered.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06024694
Study type Observational
Source IRCCS San Raffaele
Contact Andres Ferreri
Phone 0226435603
Email ferreri.clinicaltrials@hsr.it
Status Recruiting
Phase
Start date June 10, 2022
Completion date June 10, 2024
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04526834 - Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma Phase 1
Recruiting NCT06339255 - Italian Observational Study on CAR-T Therapy for Lymphoma
Recruiting NCT06026319 - CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma Phase 1
Active, not recruiting NCT05162170 - Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study
Recruiting NCT05934448 - Pembro Plus CAR T-cell Therapy in R/R in PMBCL Phase 2
Recruiting NCT04186520 - CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies Phase 1/Phase 2
Recruiting NCT04836507 - Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients Phase 1/Phase 2
Active, not recruiting NCT04875195 - A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68) Phase 2
Active, not recruiting NCT03625037 - First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma Phase 1/Phase 2
Not yet recruiting NCT06208735 - CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies Phase 1
Active, not recruiting NCT05856708 - CNS Involvement in Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)
Completed NCT05130489 - CAR T Cell Therapy Related Cardiovascular Outcomes
Not yet recruiting NCT05934084 - Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors N/A
Recruiting NCT04745559 - Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy Phase 2
Not yet recruiting NCT04600947 - Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma Phase 2
Recruiting NCT05366569 - Bio-CAR-T BS Study
Recruiting NCT06014762 - P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies Phase 1
Approved for marketing NCT05733650 - Expanded Access Program for Epcoritamab